We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Study of Pharmacological Treatment Pattern for Cannabis-induced Psychosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04945031
Recruitment Status : Completed
First Posted : June 30, 2021
Last Update Posted : June 30, 2021
Sponsor:
Information provided by (Responsible Party):
Mahidol University

Brief Summary:
A cross-sectional and retrospective chart review study was conducted at the Princess Mother National Institute on Drug Abuse Treatment (PMNIDAT), Thailand. All patients who admitted at PMNIDAT from October 2013 to September 2019 were included. Patients aged 18-65 years who met the International Classification of Disease-10 (ICD-10) criteria of CIP and Had a positive urine test of cannabis were included. Cannabis use is a component cause of psychosis.More than half of symptoms of cannabis-induced psychosis (CIP) were hallucination, delusion, irritable and anxiety. Antipsychotic drug was still a key psychotropic drugs for treatment of CIP. However, antidepressants and benzodiazepines were commonly used for treatment of other symptoms beyond psychotics

Condition or disease Intervention/treatment
Cannabis Other: cannabis

Layout table for study information
Study Type : Observational
Actual Enrollment : 317 participants
Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: The Study of Pharmacological Treatment Pattern for Cannabis-induced Psychosis
Actual Study Start Date : November 8, 2019
Actual Primary Completion Date : May 31, 2020
Actual Study Completion Date : December 31, 2020

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
cannabis-induced psychosis Other: cannabis
This study is observational study, we recorded history of substance used, symptoms and medication in a medical chart.




Primary Outcome Measures :
  1. Pharmacological treatment pattern for cannabis-induced psychosis [ Time Frame: 30 days ]
    Pharmacological treatment pattern for cannabis-induced psychosis during admission


Secondary Outcome Measures :
  1. Change of Brief psychiatric rating scale (BPRS) form the first day of admission [ Time Frame: Day1, Day 8, Day 15 and Day 22 ]
    A high BPRS score is more severe of symptoms than a lower score



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
Medical chart which diagnosis by ICD-10 with cannabis-induced psychosis who admitted at PMNIDAT from October 2013 to September 2019 at Princess Mother National Institute on Drug Abuse Treatment.
Criteria

Inclusion Criteria:

  • Patients ≥ 12 years of age
  • Patients who had been diagnosed as Cannabis-induced psychosis by International statistical Classification of Disease and Related Health problem (ICD-10) on 2016 code F12.5
  • Patients had history of use of cannabis in medical chart
  • Patients had the positive urine screening test of cannabis at the first day of admission

Exclusion Criteria:

  • Patients had psychosis from organic psychosis, defined by diagnosis by ICD-10 code F09.6
  • Unavailable data for evaluate of outcome especially data of drug use, content of drug use or urine screening test
  • Patients who cancel of medical treatment before 7 day after admission.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04945031


Locations
Layout table for location information
Thailand
Onrumpha Chuenchom
Thanyaburi, Pathum Thani, Thailand, 12110
Sponsors and Collaborators
Mahidol University
Layout table for additonal information
Responsible Party: Mahidol University
ClinicalTrials.gov Identifier: NCT04945031    
Other Study ID Numbers: MU-DT/PY-IRB2019/PY114
First Posted: June 30, 2021    Key Record Dates
Last Update Posted: June 30, 2021
Last Verified: June 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Marijuana Abuse
Shared Paranoid Disorder
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Schizophrenia